NCT00033904已完成3 期
A Multi-Center, Randomized Phase III Study of Adjuvant Oncophage® Versus Observation in Subjects With High Risk of Recurrence After Surgical Treatment for Renal Cell Carcinoma
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Agenus Inc.
- 入组人数
- 650
- 试验地点
- 76
研究概览
简要总结
Determine whether patients receiving adjuvant HSPPC-96 treatment after surgically resected, locally advanced renal cell carcinoma have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
详细描述
Primary Objective:
- The primary objective of this study is to determine whether subjects randomized to receive adjuvant HSPPC-96 after surgical resection of locally advanced renal cell carcinoma at high risk of recurrence, have improved recurrence-free survival as compared to subjects with no adjuvant treatment.
Secondary Objective:
- Determine whether subjects randomized to receive HSPPC-96 have improved survival as compared to subjects with no adjuvant treatment.
- Further characterize the safety profile of HSPPC-96.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pre-Surgery Inclusion Criteria:
- •Primary-intact resectable renal cell cancer, without known distant metastasis and be scheduled to have surgery with curative intent;
- •Tumor size greater than or equal to 5 cm OR macroscopic nodes OR renal vein thrombus OR vena cava thrombus by radiologic evaluation
- •Performance status (Zubrod / ECOG-WHO scale)less than or equal to 1 and life expectancy of greater than three months, within 2 weeks of surgery.
- •Women of child-bearing potential must have a negative urine or serum pregnancy test within 2 weeks of surgery.
- •Signed written informed consent.
- •Pre-Surgery
排除标准
- •Prior chemo-, hormonal, immuno- or radiotherapy for renal cell cancer;
- •History of primary or secondary immunodeficiency, or patients using immunosuppressive drugs, e.g. systemic corticosteroids, cyclosporin A;
- •Current malignancies at other sites or previous other cancer within the last 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin;
- •Embolization of the renal artery prior to nephrectomy;
- •Known distant metastases;
- •Active, uncontrolled infection or other serious medical illnesses.
- •Eligibility Assessment:
- •(between 2 weeks pre- and 4 weeks post-surgery)
- •Prior to randomization and entry into the tumor evaluation phase, all subjects must undergo testing to confirm that they are free of distant metastatic disease, and that they meet all other criteria.
- •Eligibility Criteria which must be assessed and confirmed prior to randomization:
- •No evidence of metastatic or residual renal carcinoma as documented by all of the following: abdominal/pelvis CT scan; chest CT scan; and brain CT or MRI scan.
- •Provide Antigenics with greater than or equal to 7 grams of viable tumor tissue
- •Adequate bone marrow function.
- •Adequate renal and hepatic function.
- •Adequate cardiac function.
- •Signed written informed consent.
- •Patients must be willing to be followed during the course of tumor evaluation and follow-up phases.
- •Male or female patients of child producing potential must agree to use adequate contraception during the treatment/observation phase of the study.
- •Patients must not use any other investigational drug for four weeks prior to the start of the tumor evaluation phase and throughout the tumor evaluation phase of the study.
研究者
研究点 (76)
Loading locations...
相似试验
招募中
3 期
Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer at Stage IIIb and IV(KCSG ST15-08): TRIUMPHGastric Cancer, Adjuvant Chemotherapy, XONCT01935778Asan Medical Center286
招募中
3 期
Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ AdenocarcinomaGastric CancerNCT04997837Fudan University433
已完成
3 期
Study of Adjuvant ONO-4538 With Resected Gastric CancerGastric CancerNCT03006705Ono Pharmaceutical Co. Ltd800
招募中
不适用
Adjuvant Radiotherapy for Stage II/III Thymoma After Complete ResectionThymomaNCT02633553Fudan University238
Unknown
3 期
Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal CancerSquamous Cell Esophageal CarcinomaNCT01216527Sun Yat-sen University430